IBM’s Quantum Gambit: Can a Lab Acquisition Outweigh a Mainframe Meltdown?
Published on 07/26/2026 at 04:50 | Redaktion boerse-global.de
On a Friday that capped one of its worst weeks in years, IBM’s stock managed a 3.74% bounce to €188.38 — a welcome reprieve, but one that does little to mask the scale of the damage. The shares have shed 27.52% since January, and just three days earlier they touched a 52-week low of €175.14. The question hanging over Armonk is whether the company’s latest move — a binding agreement to acquire HRL Laboratories, the quantum research institute jointly owned by Boeing and General Motors — represents a genuine turning point or a costly distraction from a deteriorating core business.
The deal, signed on July 23 and expected to close by the end of the third quarter pending regulatory approvals, adds silicon spin-qubit expertise to IBM’s existing roadmap for superconducting quantum computers. It follows the May 2026 announcement of Anderon, what IBM bills as the world’s first dedicated quantum wafer fab, backed by the U.S. Department of Commerce. Together, the two initiatives form a dual-pronged strategy aimed at fault-tolerant quantum systems. Boeing and GM have signaled they will continue collaborating with IBM on quantum applications post-transaction — a vote of confidence from industrial partners that the company is keen to highlight.
The timing, however, is awkward. Preliminary second-quarter results showed revenue creeping up just 1% to $17.2 billion, with software growing 5%, consulting flat, and the infrastructure business — home to the mainframe line — collapsing 7%. CEO Arvind Krishna blamed the mainframe weakness on a late-quarter shift in customer spending toward servers, storage, and memory as clients scrambled to lock down scarce infrastructure ahead of anticipated price increases, compounded by cybersecurity concerns that delayed purchasing decisions. The narrative is one of timing, not structural decay, but the market has not been forgiving. Management trimmed its full-year growth forecast to 4-5% at constant currency, and diluted earnings per share slipped 2% to $2.27.
Should investors sell immediately? Or is it worth buying IBM?
The bull case rests on the idea that the selloff has overshot. The analyst consensus target of €231.06 implies 22.7% upside from Friday’s close, and the 14-day RSI of 35.5 is flirting with oversold territory — a level that historically attracts value-oriented buyers. Proponents argue that IBM’s software momentum, combined with the quantum push, could eventually decouple the stock from the legacy hardware cycle that has punished it so severely. The HRL acquisition, in this view, is not a defensive move but an offensive bet that accelerates IBM’s transformation into a pure-play technology pioneer.
The bear case is more skeptical. Mainframe revenues cratered 42% in the quarter, and consulting remains stagnant even as specialized rivals capture an expanding share of AI-related spending. The $10 billion-plus that IBM has pledged to quantum computing over the next five years, including support for Anderon, could weigh on cash flow long before those technologies generate meaningful commercial returns. Technical indicators reinforce the caution: the stock sits 19.44% below its 200-day moving average of €233.84 and 17.61% below the 50-day average. The annualized 30-day volatility of nearly 85% underscores how violently sentiment can swing.
Institutional behavior adds another layer of concern. Unisphere Establishment and the Bank of Nova Scotia trimmed their IBM positions by 13.1% and 29.2%, respectively, during the first quarter — a sign that some large holders are losing patience with the long gestation period for quantum and AI revenues.
For now, the 52-week low of €175.14 serves as a critical floor. If that level holds, the stock may enter a consolidation phase as the market digests the lowered guidance and awaits the HRL closing. A decisive break above the 50-day moving average — currently around €228.64 — would offer the first technical evidence that Friday’s bounce is more than a dead-cat rebound. Until then, the tension between a fading hardware franchise and a high-stakes quantum bet will keep IBM in the penalty box, waiting for the market to decide which story wins.
Ad
IBM Stock: New Analysis - 26 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
